Appreciate your comments CPR. It's refreshing when people post...

Appreciate your comments CPR. It's refreshing when people post comments that contribute in a meanful way to our investment analysis.

I've been an investor for 4 years, and like many others I have been frustrated with the slow growth of this valuable drug. In fairness to MVP management, the pharmaceutical business is a slow moving beast (unless you want a COVID vaccine). Add then the unfortunate choice of the conservative UK as the opening international market, Brexit, the ultra-conservative USA FDA, the departure of the long-time CEO (despite incentives linked to performance milestones), COVID-19, and Mundipharma's woes, and it's little wonder MVP's share price is underperforming.

Unless the market hyperventilates like it did in February 2020 (think COVID vaccine), I think it will take some years to see a significant return on MVP.

It's also significant that Williams and Sharman sold MVP down heavily about 18 months ago. Most directors have only a modest investment and the CFO has none. Compare that to the big dollars Williams and Powell have recently poured into PNV and RMY shares, and you'll see which way the wind is blowing.

I have two main requests of Mr Williams (I know you read this column) and his team:

1. FDA UPDATES: On 29 August 2018, Williams and Sharman gave a detailed update of the FDA's requirements to lift its clinical hold. Since then we've only recieved "Roadshow" updates with sparse explanations on why we still have not submitted our clinical package. I've tried to follow the apparently changing FDA goalposts to understand the process, but it's got me baffled. Why, for example, has the USA launch been delayed from Q3 2022 to Q1 2024 (nearly 18 months)? Surely that deserves a detailed explanation. Is it all due to COVID or are other factors involved? If I had more specific information, I'd have more confidence in company management and in my investment choices. How about another 2018-style detailed update?
2. CONTINUOUS FLOW TECHNOLOGY: On 30 June 2020, the latest PhillipCapital research update said "MVP has flagged a possible licencing deal by end 2020." (Last bullet point on page 4) The FY20 MVP preliminary report merely states "the program continues to progress well with advancements being made in the commercialisation of Lidocaine (analgesic) & Diclofenac (anti-inflammatory APIs." I think we investors deserve more specific information instead of vague but tantilizing promises.

I'm no expert, just a mug investor trying to make a quid. But I'd appreciate more specific and transparent communication from Mr Williams and his team.